Achieved primary endpoint of LS mean reduction in LDL-C on top of maximally tolerated lipid modifying therapies at week 12 with statistically significant reduction (p<0.0001), which was sustained at week 52 (p<0.0001) -- nn-- Obicetrapib lowered LDL-C by 36.3% at week 12 and by 41.5% at week 52, compared to placebo -- nn-- Obicetrapib was well-tolerated; safety results comparable to placebo--
BOLOGNA, Italy and HUNTINGDON VALLEY, Pa., July 2, 2024 /PRNewswire/ --The Reproductive Precision Medicine Unit of Menarini Silicon Biosystems (MSB) presented last week, at the 21st World Congress of the Fetal Medicine Foundation meeting in Lisbon, Portugal, results of a large multicenter study describing their next generation non-invasive prenatal testing technology using fetal cells isolated from maternal blood. The genomic analysis of these fetal cells showed a high concordance with the analysis of fetal cells obtained from invasive diagnostic procedures. Moreover, MSB's cell-based test, under development, demonstrated its potential validity for screening genomic conditions not easily found with currently available, state of the art, non-invasive screening technologies based on cell-free DNA (cfDNA) analysis.
Menarini Group Presents Updated Data from ELECTRA and ELEVATE Combination Studies of Elacestrant (ORSERDU®) in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the ASCO 2024 Annual Meeting
Docquity, Southeast Asia's largest community of healthcare professionals (HCPs), recently supported Menarini Malaysia, a member of the Menarini Group - the world's largest Italian biopharmaceutical company, with a successful HCP education campaign.
Venatorx and Menarini Enter Agreement for Cefepime-Taniborbactam
Menarini Group and Insilico Medicine Enter Global Exclusive License Agreement
Menarini Presented Efficacy Data from Phase 1b/2 Studies of ORSERDU
Menarini Presents Progression-Free Survival Data from EMERALD Clinical Study